Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were evaluated in a phase 2 study; 51 patients had TP53 aberration (TP53 cohort) and 35 were enrolled because of age 65 years or older (elderly cohort). Both cohorts included patients with treatment-naive (TN) and re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Ahn, Inhye E., Farooqui, Mohammed Z. H., Tian, Xin, Valdez, Janet, Sun, Clare, Soto, Susan, Lotter, Jennifer, Housel, Stephanie, Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Calvo, Katherine R., Nierman, Pia, Hughes, Thomas E., Saba, Nakhle S., Marti, Gerald E., Pittaluga, Stefania, Herman, Sarah E. M., Niemann, Carsten U., Pedersen, Lone B., Geisler, Christian H., Childs, Richard, Aue, Georg, Wiestner, Adrian
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2018
Schlagworte:
Lymphoid Neoplasia
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969380/
https://ncbi.nlm.nih.gov/pubmed/29483101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-12-820910
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge